{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:55:46Z","timestamp":1788306946642,"version":"build-2803163510"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Aggressive prolactinomas (APRLs) pose a significant clinical challenge due to their high rate of regrowth and potentially life-threatening complications. In this study, we present a case of a patient with an APRL who had a trial of multiple therapeutic modalities with the aim to provide a review of molecular abnormalities and management of APRLs by corroborating our experience with previous literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 268 articles were reviewed and 46 were included. Case reports and series, and studies that investigated the molecular and\/or genetic analysis of APRLs were included. Special care was taken to include studies describing prolactinomas that would fall under the APRL subtype according to the European Society of Endocrinology guidelines; however, the author did not label the tumor as \u201caggressive\u201d or \u201catypical\u201d. Addiontionally, we present a case report of a 56-year-old man presented with an invasive APRL that was resistant to multiple treatment modalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Literature review revealed multiple molecular abnormalities of APRLs including mutations in and\/or deregulation of ADAMTS6, MMP-9, PITX1, VEGF, POU6F2, CDKN2A, and Rb genes. Mismatch repair genes, downregulation of microRNAs, and hypermethylation of specific genes including RASSF1A, p27, and MGMT were found to be directly associated with the aggressiveness of prolactinomas. APRL receptor analysis showed that low levels of estrogen receptor (ER) and an increase in somatostatin receptors (SSTR5) and epidermal growth factor receptors (EGFR) were associated with increased invasiveness and higher proliferation activity. Our patient had positive immunohistochemistry staining for PD-L1, MSH2, and MSH6, while microarray analysis revealed mutations in the CDKN2A and POU6F2 genes. Despite undergoing two surgical resections, radiotherapy, and taking dopamine agonists, the tumor continued to progress. The patient was administered pazopanib, which resulted in a positive response and the patient remained progression-free for six months. However, subsequent observations revealed tumor progression. The patient was started on PD-L1 inhibitor pembrolizumab, yet the tumor continued to progress.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>APRLs are complex tumors that require a multidisciplinary management approach. Knowledge of the molecular underpinnings of these tumors is critical for understanding their pathogenesis and identifying potential targets for precision medical therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1195792","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T13:39:51Z","timestamp":1689601191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas"],"prefix":"10.3389","volume":"14","author":[{"given":"Eduardo J.","family":"Medina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef M.","family":"Zohdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Revuelta Barbero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mayol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Pradilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Ioachimescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Garzon-Muvdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 world health organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000371806","article-title":"Aggressive pituitary tumors","volume":"101","author":"Chatzellis","year":"2015","journal-title":"Neuroendocrinology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1596024","article-title":"Clinical management of difficult to treat macroprolactinomas","volume":"14","author":"Sahakian","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2007.03.011","article-title":"Prolactinoma surgery","volume":"68","author":"Jan","year":"2007","journal-title":"Ann Endocrinol (Paris)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3892\/etm.2021.10997","article-title":"Aggressive prolactinoma (Review)","volume":"23","author":"Valea","year":"2022","journal-title":"Exp Ther Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04373.x","article-title":"Temozolomide in the management of dopamine agonist-resistant prolactinomas","volume":"76","author":"Whitelaw","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e8733","DOI":"10.1097\/MD.0000000000008733","article-title":"Treatment of aggressive prolactinoma with temozolomide: a case report and review of literature up to date","volume":"96","author":"Chen","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0493","article-title":"Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy","volume":"161","author":"Swords","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01040-4","article-title":"Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature","volume":"23","author":"Lizzul","year":"2020","journal-title":"Pituitary"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2015.00054","article-title":"Deregulation of miR-183 and KIAA0101 in aggressive and malignant pituitary tumors","volume":"2","author":"Roche","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02332","article-title":"Reduced expression of mismatch repair genes MSH6\/MSH2 directly promotes pituitary tumor growth via the ATR-Chk1 pathway","volume":"103","author":"Uraki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.3390\/ijms21082831","article-title":"MSH6\/2 and PD-L1 expressions are associated with tumor growth and invasiveness in silent pituitary adenoma subtypes","volume":"21","author":"Uraki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas\u2013diagnosis and emerging treatments","volume":"10","author":"Ieva","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.684055","article-title":"Galectin-3 and estrogen receptor alpha as prognostic markers in prolactinoma: preliminary results from a pilot study","volume":"12","author":"Bima","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"SUN","DOI":"10.1210\/js.2019-SUN-442","article-title":"SUN-442 EGFR\/ErbB2 targeted therapy for aggressive prolactinomas","volume":"3","author":"Cooper","year":"2019","journal-title":"J Endocrine Soc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0066","article-title":"Expression and function of ErbB receptors and ligands in the pituitary","volume":"18","author":"Cooper","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.773905","article-title":"Anti-VEGF therapy in refractory pituitary adenomas and pituitary carcinomas: a review","volume":"11","author":"Dai","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00290","article-title":"The epigenomics of pituitary adenoma","volume":"10","author":"Hauser","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1677\/ERC-07-0062","article-title":"A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors","volume":"14","author":"Wierinckx","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2011.00476.x","article-title":"Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors","volume":"21","author":"Wierinckx","year":"2011","journal-title":"Brain Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2017.1403682","article-title":"HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis","volume":"17","author":"Fedele","year":"2018","journal-title":"Cell Cycle"},{"key":"B27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1530\/ERC-18-0082","article-title":"ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation","volume":"25","author":"Principe","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00414","article-title":"Phase-II trials of pazopanib in metastatic neuroendocrine neoplasia (mNEN): a systematic review and meta-analysis","volume":"10","author":"Bongiovanni","year":"2020","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-020-09609-2","article-title":"Frequency and role of CDKN2A deletion in high-risk pituitary neuroendocrine tumors","volume":"31","author":"Kara","year":"2020","journal-title":"Endocr Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1022","article-title":"Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma","volume":"7","author":"Miao","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2020.02.007","article-title":"Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia","volume":"82","author":"Stiles","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24258","article-title":"Does molecular profiling of tumors using the caris molecular intelligence platform improve outcomes for cancer patients","volume":"9","author":"Carter","year":"2018","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-007-0082-2","article-title":"Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses","volume":"11","author":"Evans","year":"2008","journal-title":"Pituitary"},{"key":"B36","article-title":"Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB","volume":"55","author":"Pei","year":"1995","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.3.818","article-title":"Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker","volume":"82","author":"Bates","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1580425","article-title":"Epidermal growth factor binding sites in human pituitary macroadenomas","volume":"158","author":"Jaffrain-Rea","year":"1998","journal-title":"J Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.8.6754","article-title":"Role of matrix metalloproteinase 9 in pituitary tumor behavior","volume":"85","author":"Turner","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800965","article-title":"Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas","volume":"20","author":"Qian","year":"2007","journal-title":"Mod Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-008-1029-y","article-title":"Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells","volume":"24","author":"Huang","year":"2008","journal-title":"Neurosci Bull"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03487.x","article-title":"Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours","volume":"71","author":"McCormack","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.202","article-title":"Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas","volume":"22","author":"Qian","year":"2009","journal-title":"Mod Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1586\/erm.09.60","article-title":"Key signaling molecules in pituitary tumors","volume":"9","author":"Tanase","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4934","article-title":"Heregulin regulates prolactinoma gene expression","volume":"69","author":"Vlotides","year":"2009","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-010-9119-6","article-title":"VEGF and CD31 association in pituitary adenomas","volume":"21","author":"Cristina","year":"2010","journal-title":"Endocr Pathol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1267\/ahc.09034","article-title":"Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors","volume":"43","author":"Miyajima","year":"2010","journal-title":"Acta Histochem Cytochem."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1191","article-title":"Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up","volume":"95","author":"Raverot","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.05.020","article-title":"Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior","volume":"44","author":"Righi","year":"2013","journal-title":"Hum Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0434-4","article-title":"Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence","volume":"16","author":"S\u00e1nchez-Ortiga","year":"2013","journal-title":"Pituitary"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2014.02.010","article-title":"Implications of MGMT methylation status in pituitary adenoma","volume":"210","author":"Arya","year":"2014","journal-title":"Pathol Res Pract"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-0093-x","article-title":"Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors","volume":"46","author":"Cooper","year":"2014","journal-title":"Endocrine"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0586","article-title":"Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients","volume":"174","author":"Coli","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/cbr.2018.2589","article-title":"Expressions of matrix metalloproteinases-9 and tissue inhibitor of metalloproteinase-1 in pituitary adenomas and their relationships with prognosis","volume":"34","author":"Guo","year":"2019","journal-title":"Cancer Biother Radiopharm"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.910608","article-title":"Overexpression of DNA (Cytosine-5)-Methyltransferase 1 (DNMT1) and DNA (Cytosine-5)-Methyltransferase 3A (DNMT3A) is associated with aggressive behavior and hypermethylation of tumor suppressor genes in human pituitary adenomas","volume":"24","author":"Ma","year":"2018","journal-title":"Med Sci Monit"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02544","article-title":"MiR-137\u2019s tumor suppression on prolactinomas by targeting MITF and modulating wnt signaling pathway","volume":"104","author":"Lei","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.9.3268","article-title":"Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas","volume":"84","author":"Jaquet","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B58","article-title":"The high mobility group A2 gene is amplified and overexpressed in human prolactinomas","volume":"62","author":"Finelli","year":"2002","journal-title":"Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20282","article-title":"miR-15a and miR-16-1 down-regulation in pituitary adenomas","volume":"204","author":"Bottoni","year":"2005","journal-title":"J Cell Physiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700248","article-title":"Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas","volume":"85","author":"Qian","year":"2005","journal-title":"Lab Invest"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-007-0279-5","article-title":"MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy","volume":"115","author":"Kovacs","year":"2008","journal-title":"Acta Neuropathol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12022-009-9057-3","article-title":"Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers","volume":"20","author":"Mallea-Gil","year":"2009","journal-title":"Endocr Pathol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma","volume":"181","author":"Coopmans","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000344","article-title":"Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside","volume":"24","author":"Ben-Shlomo","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1349-2","article-title":"CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation","volume":"116","author":"Xu","year":"2014","journal-title":"J Neurooncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.17.7961","article-title":"Nerve growth factor suppresses the transforming phenotype of human prolactinomas","volume":"90","author":"Missale","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/mend.10.3.8833656","article-title":"Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism","volume":"10","author":"Missale","year":"1996","journal-title":"Mol Endocrinol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e82619","DOI":"10.1371\/journal.pone.0082619","article-title":"The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: a systematic review of the literature","volume":"8","author":"Pease","year":"2013","journal-title":"PloS One"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat Rev Genet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01029-z","article-title":"Expression patterns of ER\u03b166 and its novel variant isoform ER\u03b136 in lactotroph pituitary adenomas and associations with clinicopathological characteristics","volume":"23","author":"Mahboobifard","year":"2020","journal-title":"Pituitary"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.80.4.7714115","article-title":"Somatostatin receptor subtype gene expression in pituitary adenomas","volume":"80","author":"Miller","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.2.8636285","article-title":"Epidermal growth factor and its receptor (EGF-r) in human pituitary adenomas: EGF-r correlates with tumor aggressiveness","volume":"81","author":"LeRiche","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1210\/me.2010-0353","article-title":"HER2\/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy","volume":"25","author":"Fukuoka","year":"2011","journal-title":"Mol Endocrinol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1210\/me.2004-0182","article-title":"Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule\/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia","volume":"18","author":"Ezzat","year":"2004","journal-title":"Mol Endocrinol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2018.07.013","article-title":"Pasireotide: a potential therapeutic alternative for resistant prolactinoma","volume":"80","author":"Lasolle","year":"2019","journal-title":"Ann Endocrinol (Paris)"},{"key":"B77","article-title":"Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma","volume":"53","author":"Arita","year":"2004","journal-title":"Hiroshima J Med Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1445","article-title":"Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice","volume":"146","author":"Cristina","year":"2005","journal-title":"Endocrinology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.177790","article-title":"Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas","volume":"337","author":"Luque","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon Alfa-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"Oncologist"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.608422","article-title":"The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas","volume":"11","author":"Dai","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02611-x","article-title":"Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor","volume":"69","author":"Suteau","year":"2020","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1195792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T13:39:57Z","timestamp":1689601197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1195792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":86,"alternative-id":["10.3389\/fendo.2023.1195792"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1195792","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"article-number":"1195792"}}